Click Here For COVID-19 (Coronavirus) Studies

Trials Offered by a Specific Doctor

David Lederer, MD
(212) 305-8203

David J. Lederer, MD, MS is the Co-Director of the New York Presbyterian/Columbia University Interstitial Lung Disease Program and Pulmonary Director of the Pulmonary & Intensive Care Translational Outcomes (PICTOR) Group at Columbia University. He is the principal investigator of two NHLBI-funded studies: the MESA Lung Fibrosis Study and the Lung Transplant Body Composition Study. He is a deputy editor of the Annals of the American Thoracic Society and sits on the editorial board of the American Journal of Respiratory and Critical Care Medicine and on the statistical editorial board for Thorax. Dr. Lederer is a Senior Medical Advisor for the Pulmonary Fibrosis Foundation and a standing member of the IRAP study section at the Center for Scientific Review at the NIH. He is a member of the Technical Advisory Committee for the Scientific Registry of Transplant Recipients and a member of the Research and Scientific Advisory Board of the American Lung Association. He blogs at for patients with pulmonary fibrosis.

Clinical Studies Managed By Dr. Lederer:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with pulmonary hypertension using study drug RiociguatBayerAAAN4757
Details[CLOSED] A CT scan imaging study for lung transplant recipients with chronic lung transplant dysfunctionFluiddaAAAO2355
Details[CLOSED] Idiopathic Pulmonary Fibrosis prospective outcomesBoehringer IngelheimAAAO3508
Details[CLOSED] A study for patients with pulmonary fibrosis (PF) using study drug GBT440Global Blood TherapeuticsAAAQ8501
Details[CLOSED] A study for patients with Idiopathic Pulmonary Fibrosis using study drug FG-3019FibroGenAAAQ7503